Welcome to our dedicated page for Intellia Therape news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therape stock.
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage gene editing company whose news flow centers on the development of CRISPR-based therapies. Company announcements frequently highlight progress in its in vivo programs, including nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis and lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE). Investors following NTLA news can see updates on clinical trial data, regulatory interactions and platform developments that shape the company’s pipeline.
Recent Intellia press releases and SEC-furnished materials describe longer-term Phase 1 and Phase 1/2 data for nex-z and lonvo-z, pooled analyses of patient outcomes, and details from global Phase 3 trials such as MAGNITUDE, MAGNITUDE-2 and HAELO. News items also cover events such as temporary pauses in patient dosing, FDA clinical holds on Phase 3 nex-z trials, and subsequent company plans to work with regulators. These disclosures provide insight into both the potential and the risks associated with Intellia’s CRISPR-based candidates.
Beyond clinical results, NTLA news includes quarterly financial updates, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), and investor presentations at major healthcare conferences. Together, these items give a view into Intellia’s operational progress, capital position and strategic priorities as it advances gene editing therapies for serious diseases like ATTR amyloidosis and HAE.
This news page aggregates Intellia’s latest press releases and related market-moving information in one place, allowing readers to review clinical milestones, regulatory developments and corporate updates linked to the NTLA stock.
Intellia Therapeutics (NASDAQ: NTLA) will present at Baird’s 2020 Virtual Global Healthcare Conference on September 9, 2020, at 10:50 a.m. ET. The presentation will showcase the company's advancements in CRISPR/Cas9 technology aimed at developing curative therapeutics. A live webcast can be accessed on the company's website, with a replay available for 14 days post-event. Intellia focuses on editing disease-associated genes to treat cancer and immunological diseases, positioning itself as a leader in genome editing.
Intellia Therapeutics (NTLA) has submitted its first regulatory application to the U.K.’s MHRA for a Phase 1 study of NTLA-2001, targeting transthyretin amyloidosis, aiming to dose the first patient by year-end. The company expanded its collaboration with Regeneron, receiving $100 million to co-develop hemophilia treatments. Intellia plans to submit INDs for NTLA-5001 (acute myeloid leukemia) and NTLA-2002 (hereditary angioedema) in 2021. As of June 30, 2020, the company reported a cash position of $436.8 million, enabling operations for at least 24 months.
Intellia Therapeutics (NASDAQ: NTLA) will present its second quarter 2020 financial results and operational highlights in a conference call scheduled for August 6, 2020, at 8 a.m. ET. The company, a frontrunner in genome editing using CRISPR/Cas9 technology, aims to develop curative therapeutics both in vivo and ex vivo. Interested participants can join the call by dialing the provided numbers or access a replay on the company's website later that day. Intellia's commitment to advancing CRISPR technology positions it for significant therapeutic applications.
Intellia Therapeutics (NTLA) has successfully completed an underwritten public offering of 6,301,370 shares at $18.25 per share, raising approximately $115 million in gross proceeds. The offering included the full exercise of an option for an additional 821,917 shares. Goldman Sachs, Jefferies, and SVB Leerink served as joint book-running managers. The shares were offered under a previously filed shelf registration statement, and a final prospectus supplement detailing the offering was filed with the SEC on June 3, 2020.
Intellia Therapeutics (NASDAQ: NTLA) has announced a public offering of 5,479,453 shares at $18.25 per share, aiming to raise approximately $100 million. The offering includes a 30-day option for underwriters to buy an additional 821,917 shares. The closing of this offering is anticipated around June 5, 2020, subject to standard closing conditions. Goldman Sachs, Jefferies, and SVB Leerink are the joint book-running managers. Shares are offered under a previously effective shelf registration statement with the SEC.
Intellia Therapeutics (NASDAQ: NTLA) announced a public offering of $75 million in common stock with a 30-day option for underwriters to purchase an additional 15%. The offering is subject to market conditions, and all shares will be sold by Intellia. Goldman Sachs, Jefferies, and SVB Leerink are managing the offer. The shares are available under a shelf registration statement filed with the SEC. This announcement reflects Intellia's ongoing commitment to funding its genome editing technology using CRISPR/Cas9.
Intellia Therapeutics (NASDAQ: NTLA) showcased its innovative CRISPR/Cas9 technology during the ASGCT Annual Meeting, presenting promising data on NTLA-5001 for acute myeloid leukemia (AML) and NTLA-2002 for hereditary angioedema (HAE). The proprietary process for NTLA-5001 enables multiple gene edits in T cells, leading to enhanced therapeutic potential. Data revealed >98% efficiency in gene editing with minimal adverse translocations. NTLA-2002 demonstrated a sustained 90% reduction in kallikrein activity, indicating significant efficacy in reducing HAE attack rates. IND submissions for both drug candidates are anticipated in 2021.
Intellia Therapeutics (NASDAQ: NTLA) announced key updates in its pipeline for Q1 2020, focusing on its CRISPR/Cas9 technology. The company plans to submit INDs for its lead therapies: NTLA-2001 for transthyretin amyloidosis by mid-2020, NTLA-5001 for acute myeloid leukemia in 1H 2021, and NTLA-2002 for hereditary angioedema in 2H 2021. Intellia ended the quarter with a cash position of $250 million, expecting a runway through the end of 2021. However, research and development expenses rose, leading to a net loss of $31.8 million compared to $21.9 million in Q1 2019.
Summary not available.
Summary not available.